Tag Archives: regn

Regeneron Jumps On Favorable Cholesterol Drug Report

Regeneron (REGN) said an experimental drug it’s developing with Sanofi (SNY) was found in a late-stage trial to be effective in fighting “bad” cholesterol, even when injected once every four weeks instead of two weeks. The report makes the drug, alirocumab, easier for people with high cholesterol to take, increasing the likelihood consumers will prefer it. The drug is expected to hit the market in the third quarter of this year. Alirocumab is in a

Regeneron Q3 Earnings Miss As U.S. Eylea Sales Falter

Big-cap biotech Regeneron Pharmaceuticals (REGN) missed Wall Street’s Q3 estimates and cut the top end off the guidance range for its best-selling drug, sending the stock down 5% in early trading on the stock market today . Regeneron’s earnings, excluding one-time items, rose 5% over the year-earlier quarter to $2.52 a share, missing analysts’ consensus by 5 cents, according to Thomson Reuters. Revenue rose 22% to $726 million, missing the Street’s

Regeneron Eye Drug Beats Rivals While Amgen Sues

Biotech Regeneron Pharmaceuticals got good news and bad news Friday morning as its drug Eylea outperformed the competition in a clinical trial, but it also got sued for patent infringement by Amgen over its cholesterol drug. Investors focused on the positive, as Regeneron Pharmaceuticals (REGN) stock was up 9% in morning trading on the stock market today, above 372. Earlier, Regeneron stock touched an all-time high of 375.90. The trial made a